Multiple Sclerosis Drugs Market By Molecule Type and Route of Administration - Global Industry Analysis And Forecast To 2027
Published On : January 2019 Pages : 170 Category: Petrochemicals Report Code : CM012247
Multiple Sclerosis Drugs Market By Molecule Type (Small Molecules and Biologics) and Route of Administration (Parenteral Therapeutic Drugs and Oral Therapeutic Drugs) - Global Industry Analysis And Forecast To 2027
Industry Outlook
Multiple sclerosis (MS) is a disorder that potentially harms the central nervous system (brain & spinal cord). Multiple sclerosis (MS) the protective stealth (myelin) is attacked by the immune system which develops communication problem between the brain & rest of body. Prolonged Multiple sclerosis (MS) causes permanent damage of the nerves. The symptoms of Multiple sclerosis (MS) are dependent on the number & which nerves are damaged. There is no particular treatment for Multiple sclerosis (MS) but the treatment helps in speedy recovery. The use of Multiple Sclerosis Drugs is growing due to; increasing demand for medication for fighting the disorder & high R&D in the pharmaceutical sector. Therefore, the Multiple Sclerosis Drugs Market is anticipated to expand and has tremendous scope during the forecast period. The global Multiple Sclerosis Drugs Market anticipated to flourish in the future by growing at a significantly higher CAGR.
Market Segmentation
The global Multiple Sclerosis Drugs Market is based on segment, by Molecule Type the market is segmented into Small Molecules and Biologics, and by Route of Administration the market is segmented into Parenteral Therapeutic Drugs and Oral Therapeutic Drugs.
- Multiple Sclerosis Drugs Market, By Molecule Type
- Small Molecules
- Biologics
- Multiple Sclerosis Drugs Market, By Route of Administration
- Parenteral Therapeutic Drugs
- Oral Therapeutic Drugs
Regional Insights
On a global front, the Multiple Sclerosis Drugs Market covers North America (United States, Canada and Mexico), Europe (Germany, UK, France, Russia, Italy, Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific), South America (Brazil, Argentina, Columbia, Rest of South America) and Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA). North American region is leading the Multiple Sclerosis Drugs Market owing to advancement of healthcare sector.
Multiple Sclerosis Drugs Market, By Region
-
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The leading players in the market are Pfizer, Abbvie, Bayer, Opexa, Merck Serono, GlaxoSmithKline, Teva Pharmaceutical, AB Science, Novartis, Biogen Idec and Sanofi. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.
- Pfizer
- Abbvie
- Bayer
- Opexa
- Merck Serono
- GlaxoSmithKline
- Teva Pharmaceutical
- AB Science
- Novartis
- Biogen Idec
- Sanofi
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Multiple Sclerosis Drugs Market, By Molecule Type, Estimates and Forecast, 2017-2027 ($Million)
o Small Molecules
o Biologics
· Multiple Sclerosis Drugs Market, By Route of Administration, Estimates and Forecast, 2017-2027 ($Million)
o Parenteral Therapeutic Drugs
o Oral Therapeutic Drugs
· Multiple Sclerosis Drugs Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Multiple Sclerosis Drugs Market, By Country
o U.S. Multiple Sclerosis Drugs Market
o Canada Multiple Sclerosis Drugs Market
o Mexico Multiple Sclerosis Drugs Market
o Europe
§ Europe Multiple Sclerosis Drugs Market, By Country
o Germany Multiple Sclerosis Drugs Market
o UK Multiple Sclerosis Drugs Market
o France Multiple Sclerosis Drugs Market
o Russia Multiple Sclerosis Drugs Market
o Italy Multiple Sclerosis Drugs Market
o Rest of Europe Multiple Sclerosis Drugs Market
o Asia-Pacific
§ Asia-Pacific Multiple Sclerosis Drugs Market, By Country
o China Multiple Sclerosis Drugs Market
o Japan Multiple Sclerosis Drugs Market
o South Korea Multiple Sclerosis Drugs Market
o India Multiple Sclerosis Drugs Market
o Southeast Asia Multiple Sclerosis Drugs Market
o Rest of Asia-Pacific Multiple Sclerosis Drugs Market
o South America
§ South America Multiple Sclerosis Drugs Market, By Country
o Brazil Multiple Sclerosis Drugs Market
o Argentina Multiple Sclerosis Drugs Market
o Columbia Multiple Sclerosis Drugs Market
o Rest of South America Multiple Sclerosis Drugs Market
o Middle East and Africa
§ Middle East and Africa Multiple Sclerosis Drugs Market, By Country
o Saudi Arabia Multiple Sclerosis Drugs Market
o UAE Multiple Sclerosis Drugs Market
o Egypt Multiple Sclerosis Drugs Market
o Nigeria Multiple Sclerosis Drugs Market
o South Africa Multiple Sclerosis Drugs Market
o Rest of MEA Multiple Sclerosis Drugs Market
Table of Contents
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Multiple Sclerosis Drugs Market, By Molecule Type
5.1. Introduction
5.2. Global Multiple Sclerosis Drugs Revenue and Market Share by Molecule Type (2017-2027)
5.2.1. Global Multiple Sclerosis Drugs Revenue and Revenue Share by Molecule Type (2017-2027)
5.3. Small Molecules
5.3.1. Global Small Molecules Revenue and Growth Rate (2017-2027)
5.4. Biologics
5.4.1. Global Biologics Revenue and Growth Rate (2017-2027)
6. Multiple Sclerosis Drugs Market, By Route Of Administration
6.1. Introduction
6.2. Global Multiple Sclerosis Drugs Revenue and Market Share by Route Of Administration (2017-2027)
6.2.1. Global Multiple Sclerosis Drugs Revenue and Revenue Share by Route Of Administration (2017-2027)
6.3. Parenteral Therapeutic Drugs
6.3.1. Global Parenteral Therapeutic Drugs Revenue and Growth Rate (2017-2027)
6.4. Oral Therapeutic Drugs
6.4.1. Global Oral Therapeutic Drugs Revenue and Growth Rate (2017-2027)
7. Multiple Sclerosis Drugs Market, By Region
7.1. Introduction
7.2. Global Multiple Sclerosis Drugs Revenue and Market Share by Regions
7.2.1. Global Multiple Sclerosis Drugs Revenue by Regions (2017-2027)
7.3. North America Multiple Sclerosis Drugs by Countries
7.3.1. North America Multiple Sclerosis Drugs Revenue and Growth Rate (2017-2027)
7.3.2. North America Multiple Sclerosis Drugs Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Multiple Sclerosis Drugs by Countries
7.4.1. Europe Multiple Sclerosis Drugs Revenue and Growth Rate (2017-2027)
7.4.2. Europe Multiple Sclerosis Drugs Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Multiple Sclerosis Drugs by Countries
7.5.1. Asia-Pacific Multiple Sclerosis Drugs Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Multiple Sclerosis Drugs Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Multiple Sclerosis Drugs by Countries
7.6.1. South America Multiple Sclerosis Drugs Revenue and Growth Rate (2017-2027)
7.6.2. South America Multiple Sclerosis Drugs Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Multiple Sclerosis Drugs by Countries
7.7.1. Middle East and Africa Multiple Sclerosis Drugs Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Multiple Sclerosis Drugs Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Pfizer
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Revenue and Market Share
8.2. Abbvie
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Revenue and Market Share
8.3. Bayer
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Revenue and Market Share
8.4. Opexa
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Revenue and Market Share
8.5. Merck Serono
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Revenue and Market Share
8.6. GlaxoSmithKline
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Revenue and Market Share
8.7. Teva Pharmaceutical
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Revenue and Market Share
8.8. AB Science
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Revenue and Market Share
8.9. Novartis
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Revenue and Market Share
8.10. Biogen Idec
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Revenue and Market Share
8.11. Sanofi
8.11.1. Business Overview
8.11.2. Service Portfolio
8.11.3. Strategic Developments
8.11.4. Revenue and Market Share
9. Global Multiple Sclerosis Drugs Market Competition, by Manufacturer
9.1. Global Multiple Sclerosis Drugs Revenue and Market Share by Manufacturer (2017-2017)
9.2. Top 5 Multiple Sclerosis Drugs Manufacturer Market Share
9.3. Market Competition Trend
10. Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.1. Global Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
10.2. Multiple Sclerosis Drugs Market Forecast by Regions (2017-2027)
10.2.1. North America Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.1.1. United States Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.1.2. Canada Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.1.3. Mexico Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.2. Europe Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.2.1. Germany Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.2.2. France Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.2.3. UK Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.2.4. Russia Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.2.5. Italy Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.2.6. Rest of Europe Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.3. Asia-Pacific Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.3.1. China Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.3.2. Japan Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.3.3. Korea Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.3.4. India Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.3.5. Southeast Asia Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.3.6. Rest of Asia-Pacific Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.4. South America Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.4.1. Brazil Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.4.2. Argentina Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.4.3. Columbia Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.4.4. Rest of South America Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.5. Middle East and Africa Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.5.1. Saudi Arabia Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.5.2. United Arab Emirates Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.5.3. Egypt Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.5.4. Nigeria Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.5.5. South Africa Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.5.6. Turkey Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.2.5.7. Rest of Middle East and Africa Multiple Sclerosis Drugs Market Forecast (2017-2027)
10.3. Multiple Sclerosis Drugs Market Forecast by Molecule Type (2017-2027)
10.3.1. Multiple Sclerosis Drugs Forecast by Molecule Type (2017-2027)
10.3.2. Multiple Sclerosis Drugs Market Share Forecast by Molecule Type (2017-2027)
10.4. Multiple Sclerosis Drugs Market Forecast by Route Of Administration (2017-2027)
10.4.1. Multiple Sclerosis Drugs Forecast by Route Of Administration (2017-2027)
10.4.2. Multiple Sclerosis Drugs Market Share Forecast by Route Of Administration (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Multiple Sclerosis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Multiple Sclerosis Drugs Revenue and Revenue Share by Molecule Type (2017-2018)
Figure Global Small Molecules Revenue and Growth Rate (2017-2018)
Figure Global Biologics Revenue and Growth Rate (2017-2018)
Table Global Multiple Sclerosis Drugs Revenue and Revenue Share by Route Of Administration (2017-2018)
Figure Global Parenteral Therapeutic Drugs Revenue and Growth Rate (2017-2018)
Figure Global Oral Therapeutic Drugs Revenue and Growth Rate (2017-2018)
Table Global Multiple Sclerosis Drugs Revenue by Regions (2017-2018)
Figure North America Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure North America Multiple Sclerosis Drugs Revenue and Growth Rate (2017-2018)
Figure North America Multiple Sclerosis Drugs by Countries (2017-2018)
Figure North America Multiple Sclerosis Drugs Revenue (Million USD) by Countries (2017-2018)
Figure United States Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure United States Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure Canada Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure Mexico Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure Europe Multiple Sclerosis Drugs Revenue and Growth Rate (2017-2018)
Figure Europe Multiple Sclerosis Drugs by Countries (2017-2018)
Figure Europe Multiple Sclerosis Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Germany Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure Germany Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure France Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure UK Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure Russia Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure Italy Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure Rest of Europe Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure Asia-Pacific Multiple Sclerosis Drugs Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Multiple Sclerosis Drugs by Countries (2017-2018)
Figure Asia-Pacific Multiple Sclerosis Drugs Revenue (Million USD) by Countries (2017-2018)
Figure China Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure China Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure Japan Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure Korea Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure India Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure Southeast Asia Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure South America Multiple Sclerosis Drugs Revenue and Growth Rate (2017-2018)
Figure South America Multiple Sclerosis Drugs by Countries (2017-2018)
Figure South America Multiple Sclerosis Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure Brazil Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure Argentina Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure Columbia Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure Rest of South America Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure Middle East and Africa Multiple Sclerosis Drugs Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Multiple Sclerosis Drugs by Countries (2017-2018)
Figure Middle East and Africa Multiple Sclerosis Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure Saudi Arabia Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure United Arab Emirates Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure Egypt Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure Nigeria Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure South Africa Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure Turkey Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Multiple Sclerosis Drugs Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Table Pfizer Multiple Sclerosis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Abbvie Multiple Sclerosis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Bayer Multiple Sclerosis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Opexa Multiple Sclerosis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Merck Serono Multiple Sclerosis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table GlaxoSmithKline Multiple Sclerosis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Teva Pharmaceutical Multiple Sclerosis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table AB Science Multiple Sclerosis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Novartis Multiple Sclerosis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Biogen Idec Multiple Sclerosis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Sanofi Multiple Sclerosis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Multiple Sclerosis Drugs Market Share by Manufacturer
Figure Global Multiple Sclerosis Drugs Revenue and Market Share by Manufacturer
Table Global Multiple Sclerosis Drugs Price by Region (2017-2017)
Figure Top 5 Multiple Sclerosis Drugs Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Multiple Sclerosis Drugs Revenue (Millions USD) and Growth Rate (2018-2025)
Table Multiple Sclerosis Drugs Market Forecast by Regions (2018-2025)
Figure North America Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure United States Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Canada Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Mexico Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Europe Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Germany Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure France Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure UK Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Russia Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Italy Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Rest of Europe Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Asia-Pacific Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure China Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Japan Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Korea Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure India Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Southeast Asia Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure South America Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Brazil Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Argentina Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Columbia Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Rest of South America Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Middle East and Africa Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Saudi Arabia Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure United Arab Emirates Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Egypt Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Nigeria Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure South Africa Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Turkey Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Multiple Sclerosis Drugs Market Forecast (2018-2025)
Figure Global Multiple Sclerosis Drugs Forecast by Molecule Type (2018-2025)
Figure Global Multiple Sclerosis Drugs Market Share Forecast by Molecule Type (2018-2025)
Figure Global Multiple Sclerosis Drugs Forecast by Molecule Type (2018-2025)
Figure Global Multiple Sclerosis Drugs Forecast by Route Of Administration (2018-2025)
Figure Global Multiple Sclerosis Drugs Market Share Forecast by Route Of Administration (2018-2025)
Figure Global Multiple Sclerosis Drugs Forecast by Route Of Administration (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|